MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Pharmacotherapy"

  • 2025 International Congress

    Risk factors for central nervous system side effects of amantadine

    M. Nagai, N. Miyaue, Y. Ito, Y. Yamanishi, R. Ando, Y. Ihara (Ehime, Japan)

    Objective: The purpose of this study was to investigate the threshold blood level of amantadine and risk factors for central nervous system (CNS) side effects…
  • 2025 International Congress

    Tremor in Multifocal Motor Neuropathy

    M. Qurbonova (Dushanbe, Tajikistan)

    Objective: Study of the effect of tremor on the quality of life of patients with multifocal motor neuropathy and its dynamics in response to therapy…
  • 2025 International Congress

    Medication therapy in Parkinson’s disease patients: a cross-sectional study at the University Medical Center at Ho Chi Minh City, Vietnam

    T. Dang, T. Tran (HO CHI MINH, Viet Nam)

    Objective: To determine the rate of drugs prescribed to treat Parkinson's disease motor symptoms, the rate of the types of drug combinations, and the frequency…
  • 2025 International Congress

    Enhancing Safety and Quality of Care for Parkinson’s Disease Patients Hospitalized at a Large Academic Medical Center

    C. Kim, C. Malatt, E. Hogg, E. Tan, M. Tagliati (Los Angeles, USA)

    Objective: To implement measures to improve quality of care in Parkinson's disease (PD) patients who are hospitalized at a large academic hospital with the goal…
  • 2025 International Congress

    Medication Error Reduction Strategies in an In-patient Multimodal Intensive Neurorehabilitation and Care (i-MINC) Program

    N. Yousefzadeh, L. Hom, A. Defrank, M. Mccrossin, L. Rubin (Glen Cove, USA)

    Objective: To evaluate medication safety strategies implemented to reduce medication errors in an i-MINC Program Background: Medication mismanagement may lead to critical patient harm in…
  • 2025 International Congress

    A Phase I Study of TR-012001, a Nasal Levodopa, in Healthy Adult Japanese Male Subjects

    R. Ise, M. Kaneko, S. Haruta, Y. Sonoda, Y. Akiyoshi, C. Date, S. Nakano, T. Akagi, Y. Sumiyoshi, S. Kanazashi, I. Nagata, H. Fukase (Tokyo, Japan)

    Objective: To investigate the safety, tolerability, and pharmacokinetics of TR-012001, a nasal levodopa (LD), in healthy Japanese adult men with and without premedication with dopa…
  • 2025 International Congress

    Effect of COVID-19 Pandemic on Utilization of Parkinson’s Medications in Saudi Arabia: A Repeated Cross-Sectional Study

    K. Orayj (Abha, Saudi Arabia)

    Objective: This study aims to examine the effects of the pandemic on the patterns of medication usage for Parkinson’s Disease (PD) in Saudi Arabia. Background:…
  • 2025 International Congress

    A Proof-of-Concept Study of TR-012001, a Nasal Levodopa, in Patients With Parkinson’s Disease With OFF Episodes, Without Dopa Decarboxylase Inhibitor

    M. Nomoto, H. Yabe, R. Ando, Y. Sumiyoshi, T. Akagi, R. Ise, Y. Akiyoshi, C. Date, S. Nakano, R. Suzuki, Y. Sonoda, S. Haruta, S. Kanazashi, A. Mori, I. Nagata (Tokyo, Japan)

    Objective: To evaluate the safety, tolerability, levodopa pharmacokinetics, and exploratory efficacy of TR-012001 in Parkinson’s disease (PD). Background: TR-012001 is a novel investigational prefilled nasal…
  • 2025 International Congress

    The Role of Depression and Anxiety in the Progression of Parkinson’s Disease

    N. Dahodwala, C. Hurley, T. Kapogiannis, H. Cho, C. Caspell-Garcia, D. Weintraub, R. Dobkin (Philadelphia, USA)

    Objective: To determine the association of depression and anxiety, and their treatment, with patient-reported outcomes (PROs) in a large, online, observational cohort of people with…
  • 2025 International Congress

    Comparative Analysis of miR-29a Expression in Optimized Medical Therapy and Intestinal Infusion Therapies in Advanced Parkinson’s Disease

    I. Straka, S. Valaskova, Z. Andre, M. Minar, J. Kyselovic, A. Gazova (Bratislava, Slovakia)

    Objective: To compare the relative expression of miR-29a in patients with advanced Parkinson's disease (PD) receiving optimized medical therapy (OMT) versus intestinal infusion therapies—levodopa/carbidopa intestinal…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • …
  • 34
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • AI-Powered Detection of Freezing of Gait Using Wearable Sensor Data in Patients with Parkinson’s Disease
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • #28953 (not found)
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • VIT-D and Tics Movement Disorder
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley